...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of diabetes investigation. >Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
【24h】

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance

机译：新型选择性过氧化物酶体增殖物激活的受体-α调节剂匹马贝特对高甘油三酯血症和胰岛素抵抗患者肝和外周葡萄糖摄取的影响

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims/Introduction Pemafibrate is a novel selective peroxisome proliferator‐activated receptor‐α modulator with potent triglyceride‐lowering and high‐density lipoprotein cholesterol‐raising effects. We showed that pemafibrate decreased the homeostatic model assessment for insulin resistance in patients with dyslipidemia. To investigate how pemafibrate improves insulin sensitivity, we used a hyperinsulinemic‐euglycemic clamp technique to determine the splanchnic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. Materials and Methods A total of 27 patients with hypertriglyceridemia and insulin resistance were randomly assigned to receive pemafibrate (0.4?mg/day, b.i.d.) or placebo treatment for 12?weeks. The hyperinsulinemic‐euglycemic clamp test combined with oral glucose loading was carried out at weeks?0 and 12 to evaluate the splanchnic and peripheral glucose uptake. Results Pemafibrate, but not the placebo, significantly increased the splanchnic glucose uptake rate from baseline (19.6?±?5.9% with P =?0.005 and 2.1?±?7.4% with P =?0.78, respectively), although no significant difference between the groups was observed ( P =?0.084). Conversely, peripheral glucose uptake rate was not significantly altered. Pemafibrate, compared with the placebo, significantly decreased plasma triglycerides (?61.4?±?16.4% vs ?2.5?±?41.4%, P =?0.001), free fatty acids (?24.8?±?23.2% vs 2.0?±?26.8%, P =?0.016) and gamma‐glutamyl transpeptidase (?30?±?46 vs 10?±?19?U/L, P =?0.009) levels, and significantly increased fibroblast growth factor?21 (457.7?±?402.1 vs ?41.7?±?37.4?pg/mL, P =?0.007) levels. Conclusions Pemafibrate increased splanchnic glucose uptake from baseline in patients with hypertriglyceridemia.
机译：目的/简介匹马贝特是一种新型的选择性过氧化物酶体增殖物激活的受体α调节剂，具有有效降低甘油三酸酯和高密度脂蛋白胆固醇的作用。我们显示，血脂异常降低血脂异常患者胰岛素抵抗的稳态模型评估。为了研究肺纤维蛋白如何改善胰岛素敏感性，我们使用高胰岛素-正常血糖钳夹技术来确定高甘油三酯血症和胰岛素抵抗患者的内脏和外周葡萄糖摄取。材料和方法随机分配27例高甘油三酸酯血症和胰岛素抵抗的患者接受pemafibrate（0.4？mg /天，每日服药）或安慰剂治疗12周。在第0周和第12周进行高胰岛素-正常血糖钳夹试验与口服葡萄糖负荷相结合，以评估内脏和外周葡萄糖的摄取。结果Pemafibrate（而非安慰剂）显着提高了基线时内脏葡萄糖的摄取率（P =？0.005时分别为19.6±±5.9％，P =？0.78时分别为2.1？±？7.4％），尽管两者之间无显着差异观察到各组（P ＝ 0.084）。相反，外周葡萄糖摄取率没有明显改变。与安慰剂相比，匹马贝特显着降低血浆甘油三酸酯（分别为61.4％±16.4％和2.5％±41.4％，P = 0.001），游离脂肪酸（分别为24.8％±23.2％和2.0％±2.0％）。 26.8％，P =？0.016）和γ-谷氨酰转肽酶水平（？30？±？46 vs 10？±？19？U / L，P =？0.009）水平，并显着增加成纤维细胞生长因子？21（457.7？± 402.1 vs.41.7±37.4pg / mL，P = 0.007）水平。结论高甘油三酯血症患者血浆中贝马贝特可增加内脏葡萄糖的摄取。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号